TPI is a privately held pharmaceutical company specializing in the development and production of bioactive peptides, peptide derivatives and the technology for their transdermal delivery. One of the most extensive dermally related development programs in the industry allows TPI to offer its clients a diverse array of dermally bioactive peptides and lipopeptides in various carriers. These peptidics can be purchased in bulk, in a low toxicity solvent carrier or an appropriate nanoemulsion for the cosmoseutical or pharmaceutical formulator to incorporate into aqueous, emulsion or anhydrous product types.

Attachment of terminal alkane, alkene or phospholipid “ tails” can dramatically improve the stratum corneum (SC) diffusion properties of an oligopeptide. TPI offers a number of well-characterized lipopeptides with self-assembly properties and excellent trans SC diffusion properties. However, converting a peptide into a biosurfactant can dramatically alter the mode of action of the oligopeptide. In order to overcome this potential disadvantage for certain oligopeptides, TPI has also developed a proprietary nanoemulsion delivery system. This delivery system with either liquid or crystal cores, allowing non-derivative charged oligopeptides and polypeptides to undergo transdermal delivery.

In addition TPI offers its clients a series of research peptides, which allow numerous in vivo and in vitro experiments to be conducted to validate peptidic activity or relative performance. TPI can recommend a third party to conduct any of the tests referenced in this website. << front page